Thus, in patients with breast cancer, ex vivo IgG autoantibody responses were associated with lower recurrence-free survival and reduced intratumoral CD8+ T-cell infiltrate, whereas IgA responses correlated with germinal center activity and increased number of TLSs (94). The gene discussed is CD79A; the disease is breast carcinoma.